Context Therapeutics Inc.

Stage 4 · Declining · week 16

As of Oct 22, 2026, Context Therapeutics is in Stage 4, the downtrend phase, now in week 16 (since Jul 7, 2026). It closed at $0.24, 93.0% below its 52-week high and below its 200-day average, which is falling.

Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. More about the company

$0.24

-1.26% today

$21.6M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is CNTX early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S2 26w

S4 21w

S2 18w

S4 15w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S2 2w → S3 6w → S2 7w → S3 7w → S4 3w → S1 3w → S2 1w → S1 4w → S2 26w → S3 10w → S4 21w → S1 2w → S4 11w → S1 7w → S2 13w → S3 1w → S2 18w → S3 7w → S4 15w current

Total tracked: 165 weeks across 19 stage runs.

CNTX among Biotechnology486th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…486	CNTXContext Therapeutics Inc.	Stage 4 · wk 16	10	−38.4%

vs 52W High

-93.0%

$0.24 lo$3.36 hi

93.0% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 16

1w13w26w

Week 16, established downtrend

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-84.2%

200 DMA: $1.50 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

1.09x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-38.4%

-61.6%

-89.8%

YTD

-84.8%

-81.4%

Scan Membership

Breakout Watch

Latest: 2024-04-03

4 appearances in last 60 days. First seen: 2023-07-03.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 16 · Vol 1.09x

2026-10-21S4

Wk 16 · Vol 0.78x

2026-10-20S4

Wk 15 · Vol 0.49x

2026-10-19S4

Wk 15 · Vol 0.56x

2026-10-16S4

Wk 15 · Vol 1.44x

2026-10-15S4

Wk 15 · Vol 0.84x

2026-10-14S4

Wk 15 · Vol 0.60x

2026-10-13S4

Wk 14 · Vol 0.78x

2026-10-12S4

Wk 14 · Vol 0.31x

2026-10-09S4

Wk 14 · Vol 0.36x

2026-10-08S4

Wk 14 · Vol 0.56x

2026-10-07S4

Wk 14 · Vol 0.28x

Moving averages & range

50 DMA

$0.36

200 DMA

$1.50

52W High

$3.36

52W Low

$0.24

5D Low

$0.24

Resistance levels (recent highs)

20d High

$0.35

60d High

$0.69

120d High

$2.98

250d High

$3.36

Next resistance

+46.6%

to 20d High

ROE

-76.1%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 0.6

Context Therapeutics: quick answers

What stage is Context Therapeutics in?

As of Oct 22, 2026, Context Therapeutics (CNTX) is in Stage 4, the downtrend phase. It entered Stage 4 on Jul 7, 2026 and is in week 16. What the four stages mean

Is Context Therapeutics in an uptrend?

No. Context Therapeutics is in a Stage 4 downtrend. It trades 84.2% below its 200-day average, which is falling.

How far is Context Therapeutics from its 52-week high?

Context Therapeutics closed at $0.24 on Oct 22, 2026, 93.0% below its 52-week high of $3.36. Its 52-week low is $0.24.

How has Context Therapeutics performed over the past year?

As of Oct 22, 2026, Context Therapeutics is down 81.4% over the past year and down 84.8% so far in 2026.

Which sector and industry is Context Therapeutics in?

Context Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.